FDA's Dr. Nicole Verdun and Julie Tierney to Speak at ASGCT's 2024 Policy Summit

The American Society of Gene and Cell Therapy (ASGCT) is excited to announce that two top officials from the U.S. Food and Drug Administration (FDA) will be featured speakers at the upcoming 2024 Policy Summit on September 23-24 at the Westin Washington DC Downtown Hotel.

Nicole Verdun, MD, Super Office Director for the Office of Therapeutic Products at FDA's Center for Biologics Evaluation and Research (CBER), will participate in a panel discussion on Global Regulatory Convergence. She will be joined by other regulatory leaders from around the world to discuss international collaborations, pilots, benefits and challenges of harmonization efforts, regulatory considerations for accelerated approval pathways, and more.

Julie Tierney, Deputy Center Director for Strategy, Policy, and Legislation at CBER, will take part in a one-on-one Fireside Chat moderated by Kristin Van Goor, PhD. Tierney will dive into key issues such as implementation of the upcoming PDUFA VII, CBER's pilot programs, the regulatory guidance landscape, how FDA is responding to emerging science and trends in cell and gene therapy, and her unique perspective from her previous role in the FDA Commissioner's office.

Don't miss this chance to hear directly from two of the FDA's most prominent voices shaping the regulatory landscape for cell and gene therapies. The Policy Summit connects you with thought leaders across the field to discuss critical regulatory, legislative and payment issues impacting therapy development.

Register Today for the Policy Summit

Register now to attend in person at the Westin Washington DC Downtown Hotel or virtually. Both options include access to on-demand content for 30 days after the event. In-person registration is limited, so secure your spot early.

Shape the future of cell and gene therapy by joining ASGCT's advocacy community. Subscribe to The Advocate newsletter to stay informed on the Society's policy and advocacy initiatives.

Related Articles